Latest News

Use of PET-guided radiotherapy may enable the opportunity to incorporate biological information into the planning and delivery of radiation.
PET-Guided Radiotherapy Successfully Manages Lung and Bone Tumors

June 23rd 2025

Use of PET-guided radiotherapy may enable the opportunity to incorporate biological information into the planning and delivery of radiation.

Treatment Options and AE Considerations in First-Line EGFR+ NSCLC
Treatment Options and AE Considerations in First-Line EGFR+ NSCLC

June 20th 2025

Tarlatamab and the ES-SCLC Treatment Landscape: Managing AEs and Educating Patients
Tarlatamab and the ES-SCLC Treatment Landscape: Managing AEs and Educating Patients

June 19th 2025

Twice-Daily Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC
Twice-Daily Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC

June 6th 2025

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC
THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

June 5th 2025

Latest CME Events & Activities

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

View More

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

View More

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

26th Annual International Lung Cancer Congress®

July 25-26, 2025

Register Now!

20th Annual New York Lung Cancers Symposium®

November 15, 2025

Register Now!

Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies

View More

2nd Annual Hawaii Cancer Conference

January 24-25, 2026

Register Now!

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

View More

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

View More

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

View More

More News


Site Logo

Overview of Economic Analysis of Le Chevalier Vinorelbine Study

March 1st 1998

The costs and relative cost-effectiveness of different treatments for common illnesses are an increasing concern. New treatments for advanced non-small-cell lung cancer are having an impact. However, these treatments vary markedly in their direct financial costs, toxicity, and quality-of-life profiles. Direct comparisons between most combination regimens are not yet completed. Vinorelbine (Navelbine) is the first new agent approved in the United States for the treatment of metastatic non-small-cell lung cancer in more than a decade. We previously reported results of a post-hoc economic analysis that compared the anticipated cost-effectiveness of three regimens used to treat non-small-cell lung cancer (vinorelbine alone versus vinorelbine plus cisplatin [Platinol] versus vindesine plus cisplatin, the assumed standard treatment in Europe). Results showed that vinorelbine plus cisplatin was the most effective regimen. Using vinorelbine alone as a baseline, vinorelbine plus cisplatin added 56 days of life at an additional cost of $2,700, resulting in a cost-effectiveness ratio of $17,700 per year of life gained. Similarly, vindesine plus cisplatin added 19 days of life at a cost of $1,150, or $22,100 per year of life gained. Compared to vindesine plus cisplatin, vinorelbine plus cisplatin added 37 days of life at a cost of $1,570, or $15,500 per year of life gained. We conclude that the incremental cost-effectiveness of the vinorelbine plus cisplatin regimen was less than most commonly accepted medical interventions. If vinorelbine is preferred because of its favorable toxicity profile, the additional effectiveness of cisplatin added substantial efficacy at an acceptable cost.[ONCOLOGY(Suppl 4):14-17, 1998]